IL204948A - Β - single ifn from one to a mutated fc lgg segment - Google Patents

Β - single ifn from one to a mutated fc lgg segment

Info

Publication number
IL204948A
IL204948A IL204948A IL20494810A IL204948A IL 204948 A IL204948 A IL 204948A IL 204948 A IL204948 A IL 204948A IL 20494810 A IL20494810 A IL 20494810A IL 204948 A IL204948 A IL 204948A
Authority
IL
Israel
Prior art keywords
lgg
mutated
fragment
fused
single ifn
Prior art date
Application number
IL204948A
Other languages
English (en)
Hebrew (he)
Other versions
IL204948A0 (en
Inventor
Peter Hjelmstrom
Markus Imhof
George Feger
Nigel Jenkins
Phillippe Dupraz
Christine Power
Laurent Magenant
Phillippe Chatellard
Renata Pankiewicz
Vincent Dechavanne
Original Assignee
Merck Serono Sa
Peter Hjelmstrom
Markus Imhof
George Feger
Nigel Jenkins
Phillippe Dupraz
Christine Power
Laurent Magenant
Phillippe Chatellard
Renata Pankiewicz
Vincent Dechavanne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa, Peter Hjelmstrom, Markus Imhof, George Feger, Nigel Jenkins, Phillippe Dupraz, Christine Power, Laurent Magenant, Phillippe Chatellard, Renata Pankiewicz, Vincent Dechavanne filed Critical Merck Serono Sa
Publication of IL204948A0 publication Critical patent/IL204948A0/en
Publication of IL204948A publication Critical patent/IL204948A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL204948A 2007-10-22 2010-04-08 Β - single ifn from one to a mutated fc lgg segment IL204948A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07118980 2007-10-22
US714207P 2007-12-11 2007-12-11
PCT/EP2008/064224 WO2009053368A1 (en) 2007-10-22 2008-10-21 Single ifn-beta fused to a mutated igg fc fragment

Publications (2)

Publication Number Publication Date
IL204948A0 IL204948A0 (en) 2010-11-30
IL204948A true IL204948A (en) 2015-11-30

Family

ID=39048918

Family Applications (1)

Application Number Title Priority Date Filing Date
IL204948A IL204948A (en) 2007-10-22 2010-04-08 Β - single ifn from one to a mutated fc lgg segment

Country Status (6)

Country Link
EP (1) EP2203180B1 (enExample)
JP (1) JP5314033B2 (enExample)
AU (1) AU2008314697B2 (enExample)
ES (1) ES2400107T3 (enExample)
IL (1) IL204948A (enExample)
WO (1) WO2009053368A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534399A (en) 2002-01-25 2008-08-29 G2 Therapies Ltd Monoclonal antibodies against extracellular loops of C5aR
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP3415529B1 (en) 2007-09-26 2020-11-04 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
CN104193824A (zh) 2008-02-20 2014-12-10 G2炎症私人有限公司 人源化抗-C5aR抗体
TWI682995B (zh) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
JP5837821B2 (ja) 2009-09-24 2015-12-24 中外製薬株式会社 抗体定常領域改変体
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
US9493543B2 (en) 2010-02-16 2016-11-15 Novo Nordisk A/S Factor VIII fusion protein
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
HRP20191305T1 (hr) 2010-07-09 2019-10-18 Bioverativ Therapeutics Inc. Preradive jednolančane molekule i polipeptidi izrađeni koristeći iste
TWI638833B (zh) * 2010-11-30 2018-10-21 中外製藥股份有限公司 細胞傷害誘導治療劑
CN102585013B (zh) * 2011-01-07 2014-04-23 中国人民解放军军事医学科学院生物工程研究所 一种含有ω干扰素的融合蛋白及制备方法
PL2718322T3 (pl) * 2011-06-06 2019-07-31 Novo Nordisk A/S Lecznicze przeciwciała
WO2013011062A2 (en) * 2011-07-18 2013-01-24 Novo Nordisk A/S Oscar antagonists
ES2732712T3 (es) 2011-10-31 2019-11-25 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno que tiene una conjugación regulada entre la cadena pesada y la cadena ligera
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
CN105764922B (zh) 2013-09-27 2020-07-17 中外制药株式会社 多肽异源多聚体的制备方法
KR102568808B1 (ko) 2014-04-07 2023-08-18 추가이 세이야쿠 가부시키가이샤 면역활성화 항원 결합 분자
SG11201609370QA (en) 2014-05-13 2016-12-29 Chugai Pharmaceutical Co Ltd T cell-redirected antigen-binding molecule for cells having immunosuppression function
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
KR20210013299A (ko) * 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
TWI711630B (zh) 2014-11-21 2020-12-01 美商必治妥美雅史谷比公司 抗ｃｄ７３抗體及其用途
PL3221346T3 (pl) 2014-11-21 2021-03-08 Bristol-Myers Squibb Company Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
CN107743494B (zh) 2015-06-02 2022-04-29 诺和诺德股份有限公司 具有极性重组延伸体的胰岛素
EP3355931B1 (en) 2015-10-01 2024-06-26 Novo Nordisk A/S Protein conjugates
WO2017086367A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
DK3380522T5 (da) 2015-11-25 2024-09-30 Visterra Inc Antistofmolekyler til april og anvendelser deraf
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
WO2017132376A1 (en) 2016-01-27 2017-08-03 Just Biotherapeutics, Inc. Hybrid promoter and uses thereof
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
CA3016424A1 (en) 2016-03-14 2017-09-21 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
MA49339A (fr) * 2017-04-05 2020-02-12 Novo Nordisk As Conjugués insuline-fc à extension oligomère
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
CA3118892A1 (en) 2018-11-08 2020-05-14 Orionis Biosciences, Inc. Modulation of dendritic cell lineages
CA3121699A1 (en) * 2018-12-05 2020-06-11 Morphosys Ag Multispecific antigen-binding molecules
PH12021552960A1 (en) 2019-07-10 2022-07-25 Chugai Pharmaceutical Co Ltd Claudin-6 binding molecules and uses thereof
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
KR20230159831A (ko) * 2021-02-22 2023-11-22 압데라 테라퓨틱스 인크. 표적화된 방사성 동위원소 요법을 위한 면역접합체
CN121293357A (zh) 2022-08-22 2026-01-09 雅博得乐医疗公司 Dll3结合分子及其用途
US12600794B2 (en) 2024-07-23 2026-04-14 Abdera Therapeutics Inc. 5T4 binding polypeptides and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100480266C (zh) * 1998-10-16 2009-04-22 拜奥根Idec马萨诸塞公司 干扰素-β融合蛋白及用途
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
JP2006513139A (ja) * 2002-07-03 2006-04-20 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 治療薬の全身性送達のための中央部気道投与
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
AU2006207471A1 (en) * 2005-01-24 2006-07-27 Laboratoires Serona S.A. Use of soluble CD164 variants in inflammatory and/or autoimmune disorders
MX2007014889A (es) * 2005-05-26 2008-02-19 Schering Corp Fusion de interferon-inmunoglobulina g.

Also Published As

Publication number Publication date
WO2009053368A1 (en) 2009-04-30
EP2203180A1 (en) 2010-07-07
EP2203180B1 (en) 2012-11-21
JP2011500073A (ja) 2011-01-06
ES2400107T3 (es) 2013-04-05
AU2008314697A1 (en) 2009-04-30
AU2008314697B2 (en) 2013-08-29
JP5314033B2 (ja) 2013-10-16
IL204948A0 (en) 2010-11-30

Similar Documents

Publication Publication Date Title
IL204948A0 (en) SINGLE IFN - ?? FUSED TO MUTATED lgG Fc FRAGMENT
EP2118129A4 (en) ISOLATED PHOSPHOLIPID PROTEIN PARTICLES
EP2448972A4 (en) IMMUNOGLOBULIN FC POLYPEPTIDES
IL202128A0 (en) Immunoglobulin fusion proteins
IL202443A0 (en) Rage fusion proteins
IL201791A (en) Interferon-adapted polypeptides in the cell
PL3118220T3 (pl) Białko
GB0721686D0 (en) Polypeptides
PL2173381T3 (pl) Polipeptydy o zmodyfikowanych funkcjach efektorowych wiążące się z receptorem Fc
IL202441A0 (en) Glass ceramic armor material
AU321070S (en) Handle
ZA201000283B (en) Reinigung pegylierter polypeptide
LT2144924T (lt) Sulieto baltymo vakcina
GB2445928B (en) Retractable handle assembly
GB0725153D0 (en) Protein analysis
GB0715957D0 (en) Saftey switch
GB0719231D0 (en) Protein
GB0725201D0 (en) Peptide fusion proteins
GB0712302D0 (en) Chrondroitinase polypeptides
GB0719492D0 (en) Grinder for electrodes
GB0700759D0 (en) Novel fusion protein
TWI320491B (en) Multifunctional glasses
GB0720563D0 (en) Protein
GB0805426D0 (en) handle
GB0709707D0 (en) Novel fusion protein

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees
NE Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967)